Stem definition | Drug id | CAS RN |
---|---|---|
testosterone reductase inhibitors | 973 | 164656-23-9 |
Dose | Unit | Route |
---|---|---|
0.50 | mg | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 0.50 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.01 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 60 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Date | Agency | Company | Orphan |
---|---|---|---|
Nov. 20, 2001 | FDA | GLAXOSMITHKLINE |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Accidental exposure to product | 39.95 | 38.02 | 10 | 153 | 27395 | 63461464 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Drug dispensed to wrong patient | 168.02 | 12.26 | 45 | 26613 | 479 | 34929794 |
Conjunctivitis allergic | 124.56 | 12.26 | 43 | 26615 | 1127 | 34929146 |
Mycotic allergy | 116.82 | 12.26 | 35 | 26623 | 573 | 34929700 |
Spirometry abnormal | 114.97 | 12.26 | 36 | 26622 | 688 | 34929585 |
Sleep disorder due to a general medical condition | 112.26 | 12.26 | 62 | 26596 | 5159 | 34925114 |
Mite allergy | 111.87 | 12.26 | 35 | 26623 | 667 | 34929606 |
Dust allergy | 107.03 | 12.26 | 36 | 26622 | 870 | 34929403 |
Antimicrobial susceptibility test resistant | 105.33 | 12.26 | 29 | 26629 | 345 | 34929928 |
Orthostatic hypotension | 102.20 | 12.26 | 112 | 26546 | 25807 | 34904466 |
Minimum inhibitory concentration | 94.69 | 12.26 | 23 | 26635 | 159 | 34930114 |
Therapeutic response delayed | 85.98 | 12.26 | 28 | 26630 | 610 | 34929663 |
Urinary retention | 80.95 | 12.26 | 118 | 26540 | 36170 | 34894103 |
Breast cancer | 79.50 | 12.26 | 22 | 26636 | 267 | 34930006 |
Asthma | 78.68 | 12.26 | 127 | 26531 | 42529 | 34887744 |
Wrong patient received product | 78.43 | 12.26 | 39 | 26619 | 2615 | 34927658 |
Sopor | 74.95 | 12.26 | 67 | 26591 | 12069 | 34918204 |
Gynaecomastia | 70.51 | 12.26 | 60 | 26598 | 10120 | 34920153 |
Toxicity to various agents | 65.01 | 12.26 | 36 | 26622 | 200326 | 34729947 |
Wheezing | 62.78 | 12.26 | 113 | 26545 | 41289 | 34888984 |
Breast tenderness | 54.68 | 12.26 | 21 | 26637 | 750 | 34929523 |
Normochromic normocytic anaemia | 53.65 | 12.26 | 36 | 26622 | 4251 | 34926022 |
Prostate cancer | 49.94 | 12.26 | 100 | 26558 | 39549 | 34890724 |
Product administration error | 48.38 | 12.26 | 61 | 26597 | 16283 | 34913990 |
Fall | 47.90 | 12.26 | 291 | 26367 | 202594 | 34727679 |
Dysuria | 47.55 | 12.26 | 79 | 26579 | 27073 | 34903200 |
Product dispensing error | 45.55 | 12.26 | 38 | 26620 | 6236 | 34924037 |
Breast pain | 45.23 | 12.26 | 22 | 26636 | 1406 | 34928867 |
Full blood count abnormal | 44.98 | 12.26 | 63 | 26595 | 18605 | 34911668 |
Completed suicide | 44.81 | 12.26 | 10 | 26648 | 98158 | 34832115 |
Expired product administered | 44.09 | 12.26 | 29 | 26629 | 3312 | 34926961 |
Nipple pain | 40.80 | 12.26 | 18 | 26640 | 919 | 34929354 |
Wrong product administered | 40.17 | 12.26 | 33 | 26625 | 5301 | 34924972 |
Prostatomegaly | 40.13 | 12.26 | 33 | 26625 | 5308 | 34924965 |
Product storage error | 38.97 | 12.26 | 39 | 26619 | 8083 | 34922190 |
Dyspnoea | 38.80 | 12.26 | 448 | 26210 | 376334 | 34553939 |
Erectile dysfunction | 37.42 | 12.26 | 61 | 26597 | 20576 | 34909697 |
Foveal degeneration | 37.08 | 12.26 | 6 | 26652 | 0 | 34930273 |
Prostatic specific antigen increased | 34.56 | 12.26 | 49 | 26609 | 14631 | 34915642 |
Syncope | 33.98 | 12.26 | 149 | 26509 | 91302 | 34838971 |
Breast enlargement | 33.36 | 12.26 | 13 | 26645 | 483 | 34929790 |
5-alpha-reductase deficiency | 32.92 | 12.26 | 6 | 26652 | 6 | 34930267 |
Cardiac failure | 32.64 | 12.26 | 147 | 26511 | 91101 | 34839172 |
Asthenia | 30.96 | 12.26 | 304 | 26354 | 244947 | 34685326 |
Forced vital capacity decreased | 30.89 | 12.26 | 14 | 26644 | 762 | 34929511 |
Tachyarrhythmia | 30.74 | 12.26 | 24 | 26634 | 3584 | 34926689 |
Productive cough | 30.52 | 12.26 | 80 | 26578 | 37733 | 34892540 |
Vertigo | 30.48 | 12.26 | 63 | 26595 | 25473 | 34904800 |
Nodule | 29.56 | 12.26 | 31 | 26627 | 6788 | 34923485 |
Subarachnoid haematoma | 29.15 | 12.26 | 10 | 26648 | 257 | 34930016 |
Pulmonary function test abnormal | 28.15 | 12.26 | 20 | 26638 | 2590 | 34927683 |
Dark circles under eyes | 28.03 | 12.26 | 7 | 26651 | 55 | 34930218 |
Drug abuse | 26.48 | 12.26 | 22 | 26636 | 99074 | 34831199 |
Drug interaction | 26.07 | 12.26 | 275 | 26383 | 225671 | 34704602 |
Ossicle disorder | 26.03 | 12.26 | 6 | 26652 | 32 | 34930241 |
Malaise | 25.74 | 12.26 | 235 | 26423 | 185590 | 34744683 |
Arteriosclerosis coronary artery | 25.53 | 12.26 | 39 | 26619 | 12446 | 34917827 |
Haematuria | 25.41 | 12.26 | 90 | 26568 | 49976 | 34880297 |
Obesity | 24.62 | 12.26 | 39 | 26619 | 12839 | 34917434 |
Diffuse idiopathic skeletal hyperostosis | 24.16 | 12.26 | 6 | 26652 | 46 | 34930227 |
Hyponatraemic syndrome | 23.79 | 12.26 | 8 | 26650 | 193 | 34930080 |
Cerebral haematoma | 23.70 | 12.26 | 23 | 26635 | 4592 | 34925681 |
Disorganised speech | 22.96 | 12.26 | 12 | 26646 | 893 | 34929380 |
Breast induration | 22.48 | 12.26 | 4 | 26654 | 3 | 34930270 |
Eye haematoma | 22.30 | 12.26 | 6 | 26652 | 65 | 34930208 |
Rectal haemorrhage | 21.85 | 12.26 | 74 | 26584 | 40175 | 34890098 |
Multiple organ dysfunction syndrome | 21.71 | 12.26 | 16 | 26642 | 76550 | 34853723 |
Gait disturbance | 21.22 | 12.26 | 124 | 26534 | 85016 | 34845257 |
Product dose omission issue | 20.93 | 12.26 | 37 | 26621 | 119674 | 34810599 |
Breast mass | 20.69 | 12.26 | 10 | 26648 | 630 | 34929643 |
Pollakiuria | 20.56 | 12.26 | 46 | 26612 | 19628 | 34910645 |
Presyncope | 20.41 | 12.26 | 45 | 26613 | 19014 | 34911259 |
Myoclonic epilepsy | 20.21 | 12.26 | 12 | 26646 | 1145 | 34929128 |
FEV1/FVC ratio decreased | 19.81 | 12.26 | 6 | 26652 | 102 | 34930171 |
Subdural haematoma | 19.41 | 12.26 | 46 | 26612 | 20375 | 34909898 |
Semen volume decreased | 19.34 | 12.26 | 8 | 26650 | 348 | 34929925 |
Sepsis | 19.23 | 12.26 | 64 | 26594 | 166497 | 34763776 |
Invasive ductal breast carcinoma | 19.13 | 12.26 | 5 | 26653 | 48 | 34930225 |
Genitalia external ambiguous | 18.95 | 12.26 | 7 | 26651 | 224 | 34930049 |
Loss of personal independence in daily activities | 18.90 | 12.26 | 62 | 26596 | 33117 | 34897156 |
Intraventricular haemorrhage | 18.89 | 12.26 | 18 | 26640 | 3513 | 34926760 |
Drug ineffective | 18.77 | 12.26 | 241 | 26417 | 456510 | 34473763 |
Lower urinary tract symptoms | 18.66 | 12.26 | 7 | 26651 | 234 | 34930039 |
Obstructive airways disorder | 18.22 | 12.26 | 38 | 26620 | 15456 | 34914817 |
Breast cancer male | 18.18 | 12.26 | 8 | 26650 | 406 | 34929867 |
Procedural haemorrhage | 18.08 | 12.26 | 15 | 26643 | 2442 | 34927831 |
Pemphigoid | 17.62 | 12.26 | 27 | 26631 | 8639 | 34921634 |
Autonomic nervous system imbalance | 17.59 | 12.26 | 15 | 26643 | 2536 | 34927737 |
Death | 17.48 | 12.26 | 207 | 26451 | 397842 | 34532431 |
Occupational exposure to air contaminants | 17.35 | 12.26 | 6 | 26652 | 158 | 34930115 |
Urine flow decreased | 16.91 | 12.26 | 11 | 26647 | 1233 | 34929040 |
Pain | 16.61 | 12.26 | 90 | 26568 | 204585 | 34725688 |
Asthma-chronic obstructive pulmonary disease overlap syndrome | 16.57 | 12.26 | 11 | 26647 | 1276 | 34928997 |
Loss of consciousness | 16.04 | 12.26 | 113 | 26545 | 82554 | 34847719 |
Nausea | 16.00 | 12.26 | 174 | 26484 | 339734 | 34590539 |
Hyperkalaemia | 15.97 | 12.26 | 99 | 26559 | 69290 | 34860983 |
Wrong strength | 15.57 | 12.26 | 5 | 26653 | 104 | 34930169 |
Tongue oedema | 15.51 | 12.26 | 15 | 26643 | 2982 | 34927291 |
Respiratory symptom | 15.41 | 12.26 | 12 | 26646 | 1785 | 34928488 |
Foetal exposure during pregnancy | 15.27 | 12.26 | 5 | 26653 | 38096 | 34892177 |
Urinary tract infection | 15.19 | 12.26 | 113 | 26545 | 83968 | 34846305 |
Hepatocellular injury | 14.96 | 12.26 | 44 | 26614 | 22167 | 34908106 |
Haemorrhage | 14.92 | 12.26 | 78 | 26580 | 51292 | 34878981 |
Libido decreased | 14.65 | 12.26 | 18 | 26640 | 4678 | 34925595 |
Atrial fibrillation | 14.56 | 12.26 | 150 | 26508 | 122243 | 34808030 |
Prostatic haemorrhage | 14.50 | 12.26 | 6 | 26652 | 261 | 34930012 |
Treatment failure | 14.25 | 12.26 | 9 | 26649 | 46688 | 34883585 |
Medical device site haemorrhage | 14.24 | 12.26 | 5 | 26653 | 138 | 34930135 |
Febrile neutropenia | 14.18 | 12.26 | 55 | 26603 | 136794 | 34793479 |
Off label use | 14.18 | 12.26 | 230 | 26428 | 419294 | 34510979 |
Abnormal sleep-related event | 13.93 | 12.26 | 7 | 26651 | 480 | 34929793 |
Hypoglycaemia | 13.88 | 12.26 | 80 | 26578 | 54560 | 34875713 |
Cardio-respiratory arrest | 13.88 | 12.26 | 13 | 26645 | 55260 | 34875013 |
Blood immunoglobulin E increased | 13.66 | 12.26 | 13 | 26645 | 2533 | 34927740 |
Arteriosclerosis | 13.66 | 12.26 | 29 | 26629 | 11939 | 34918334 |
Product use in unapproved indication | 13.65 | 12.26 | 45 | 26613 | 117454 | 34812819 |
Dyspnoea exertional | 13.47 | 12.26 | 67 | 26591 | 43212 | 34887061 |
Body mass index increased | 13.38 | 12.26 | 9 | 26649 | 1066 | 34929207 |
Cough | 13.38 | 12.26 | 174 | 26484 | 149966 | 34780307 |
Vascular dementia | 13.36 | 12.26 | 7 | 26651 | 524 | 34929749 |
Blood gases abnormal | 13.25 | 12.26 | 6 | 26652 | 326 | 34929947 |
Blood pressure systolic increased | 13.17 | 12.26 | 43 | 26615 | 22909 | 34907364 |
Lactic acidosis | 13.16 | 12.26 | 57 | 26601 | 34715 | 34895558 |
Benign prostatic hyperplasia | 13.08 | 12.26 | 32 | 26626 | 14463 | 34915810 |
Forced expiratory volume decreased | 12.89 | 12.26 | 14 | 26644 | 3189 | 34927084 |
Breast disorder male | 12.86 | 12.26 | 3 | 26655 | 17 | 34930256 |
Hyperkeratosis | 12.73 | 12.26 | 15 | 26643 | 3734 | 34926539 |
Testicular pain | 12.55 | 12.26 | 13 | 26645 | 2805 | 34927468 |
Sputum increased | 12.53 | 12.26 | 12 | 26646 | 2358 | 34927915 |
Respiratory arrest | 12.50 | 12.26 | 3 | 26655 | 28040 | 34902233 |
Lung hyperinflation | 12.33 | 12.26 | 8 | 26650 | 892 | 34929381 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Conjunctivitis allergic | 142.68 | 13.08 | 41 | 21774 | 1679 | 79720894 |
Spirometry abnormal | 131.68 | 13.08 | 34 | 21781 | 925 | 79721648 |
Antimicrobial susceptibility test resistant | 128.23 | 13.08 | 28 | 21787 | 360 | 79722213 |
Mite allergy | 123.29 | 13.08 | 34 | 21781 | 1196 | 79721377 |
Drug dispensed to wrong patient | 121.58 | 13.08 | 30 | 21785 | 676 | 79721897 |
Dust allergy | 120.23 | 13.08 | 35 | 21780 | 1501 | 79721072 |
Minimum inhibitory concentration | 118.43 | 13.08 | 23 | 21792 | 157 | 79722416 |
Mycotic allergy | 116.20 | 13.08 | 34 | 21781 | 1485 | 79721088 |
Sleep disorder due to a general medical condition | 107.89 | 13.08 | 60 | 21755 | 14217 | 79708356 |
Orthostatic hypotension | 102.84 | 13.08 | 100 | 21715 | 56064 | 79666509 |
Therapeutic response delayed | 93.73 | 13.08 | 27 | 21788 | 1115 | 79721458 |
Urinary retention | 77.01 | 13.08 | 86 | 21729 | 56544 | 79666029 |
Sopor | 76.38 | 13.08 | 67 | 21748 | 32943 | 79689630 |
Prostate cancer | 75.93 | 13.08 | 67 | 21748 | 33201 | 79689372 |
Wrong patient received product | 69.49 | 13.08 | 31 | 21784 | 4587 | 79717986 |
Drug interaction | 69.40 | 13.08 | 260 | 21555 | 414923 | 79307650 |
Gynaecomastia | 62.78 | 13.08 | 34 | 21781 | 7647 | 79714926 |
Normochromic normocytic anaemia | 62.59 | 13.08 | 34 | 21781 | 7693 | 79714880 |
Cardiac failure | 56.08 | 13.08 | 128 | 21687 | 154714 | 79567859 |
Wheezing | 54.49 | 13.08 | 107 | 21708 | 116557 | 79606016 |
Asthma | 53.79 | 13.08 | 116 | 21699 | 134979 | 79587594 |
Syncope | 52.87 | 13.08 | 137 | 21678 | 179312 | 79543261 |
Haematuria | 51.77 | 13.08 | 78 | 21737 | 68758 | 79653815 |
Expired product administered | 51.55 | 13.08 | 29 | 21786 | 7022 | 79715551 |
Erectile dysfunction | 49.24 | 13.08 | 37 | 21778 | 14627 | 79707946 |
Pain | 48.10 | 13.08 | 74 | 21741 | 703728 | 79018845 |
Product dispensing error | 47.98 | 13.08 | 35 | 21780 | 13228 | 79709345 |
Full blood count abnormal | 47.52 | 13.08 | 57 | 21758 | 40417 | 79682156 |
Wrong product administered | 47.45 | 13.08 | 30 | 21785 | 8982 | 79713591 |
Fall | 47.28 | 13.08 | 260 | 21555 | 487369 | 79235204 |
Toxicity to various agents | 45.09 | 13.08 | 30 | 21785 | 421510 | 79301063 |
Arteriosclerosis coronary artery | 44.94 | 13.08 | 38 | 21777 | 17778 | 79704795 |
Completed suicide | 44.48 | 13.08 | 7 | 21808 | 245760 | 79476813 |
Product administration error | 42.66 | 13.08 | 48 | 21767 | 31798 | 79690775 |
Nipple pain | 42.43 | 13.08 | 14 | 21801 | 912 | 79721661 |
Acute kidney injury | 41.98 | 13.08 | 264 | 21551 | 519140 | 79203433 |
Prostatomegaly | 41.84 | 13.08 | 20 | 21795 | 3463 | 79719110 |
Hyperkalaemia | 40.77 | 13.08 | 94 | 21721 | 114304 | 79608269 |
Dyspnoea | 39.94 | 13.08 | 383 | 21432 | 856642 | 78865931 |
Atrial fibrillation | 39.04 | 13.08 | 131 | 21684 | 197755 | 79524818 |
Asthenia | 38.83 | 13.08 | 256 | 21559 | 511433 | 79211140 |
Tachyarrhythmia | 38.73 | 13.08 | 24 | 21791 | 6938 | 79715635 |
Subarachnoid haematoma | 38.28 | 13.08 | 10 | 21805 | 285 | 79722288 |
Prostatic specific antigen increased | 36.65 | 13.08 | 27 | 21788 | 10359 | 79712214 |
Pulmonary function test abnormal | 35.70 | 13.08 | 19 | 21796 | 4125 | 79718448 |
Nausea | 34.54 | 13.08 | 140 | 21675 | 957056 | 78765517 |
Productive cough | 34.17 | 13.08 | 75 | 21740 | 88256 | 79634317 |
Drug intolerance | 33.75 | 13.08 | 15 | 21800 | 264104 | 79458469 |
Cerebral haematoma | 33.45 | 13.08 | 23 | 21792 | 7919 | 79714654 |
Subdural haematoma | 33.24 | 13.08 | 42 | 21773 | 31392 | 79691181 |
Dysuria | 33.11 | 13.08 | 54 | 21761 | 50897 | 79671676 |
Treatment failure | 32.86 | 13.08 | 4 | 21811 | 170482 | 79552091 |
Ossicle disorder | 32.16 | 13.08 | 6 | 21809 | 32 | 79722541 |
Rectal haemorrhage | 32.06 | 13.08 | 67 | 21748 | 76233 | 79646340 |
Alopecia | 31.40 | 13.08 | 12 | 21803 | 231343 | 79491230 |
Forced vital capacity decreased | 30.45 | 13.08 | 13 | 21802 | 1730 | 79720843 |
Drug ineffective | 30.31 | 13.08 | 173 | 21642 | 1080740 | 78641833 |
Breast tenderness | 30.25 | 13.08 | 14 | 21801 | 2254 | 79720319 |
Joint swelling | 30.23 | 13.08 | 21 | 21794 | 288625 | 79433948 |
Intraventricular haemorrhage | 30.14 | 13.08 | 18 | 21797 | 4869 | 79717704 |
Product storage error | 29.88 | 13.08 | 29 | 21786 | 16197 | 79706376 |
Diffuse idiopathic skeletal hyperostosis | 29.53 | 13.08 | 6 | 21809 | 53 | 79722520 |
Semen volume decreased | 28.42 | 13.08 | 6 | 21809 | 65 | 79722508 |
Vertigo | 27.11 | 13.08 | 59 | 21756 | 69023 | 79653550 |
Obstructive airways disorder | 27.06 | 13.08 | 38 | 21777 | 31421 | 79691152 |
Hypoglycaemia | 26.31 | 13.08 | 74 | 21741 | 101520 | 79621053 |
Pemphigoid | 25.66 | 13.08 | 26 | 21789 | 15289 | 79707284 |
Contraindicated product administered | 25.30 | 13.08 | 6 | 21809 | 157532 | 79565041 |
Lactic acidosis | 25.26 | 13.08 | 58 | 21757 | 70301 | 79652272 |
Disorganised speech | 24.96 | 13.08 | 12 | 21803 | 2105 | 79720468 |
Therapeutic product effect decreased | 24.86 | 13.08 | 7 | 21808 | 163856 | 79558717 |
Arteriosclerosis | 23.61 | 13.08 | 27 | 21788 | 18200 | 79704373 |
Occupational exposure to air contaminants | 23.42 | 13.08 | 6 | 21809 | 158 | 79722415 |
Eye haematoma | 23.28 | 13.08 | 6 | 21809 | 162 | 79722411 |
Infusion related reaction | 22.49 | 13.08 | 18 | 21797 | 230219 | 79492354 |
Dyspnoea exertional | 22.13 | 13.08 | 63 | 21752 | 87010 | 79635563 |
Presyncope | 22.06 | 13.08 | 40 | 21775 | 41014 | 79681559 |
Lower urinary tract symptoms | 21.92 | 13.08 | 6 | 21809 | 205 | 79722368 |
Benign prostatic hyperplasia | 21.85 | 13.08 | 21 | 21794 | 11591 | 79710982 |
Breast enlargement | 21.79 | 13.08 | 10 | 21805 | 1579 | 79720994 |
Gait disturbance | 21.63 | 13.08 | 113 | 21702 | 207393 | 79515180 |
Nodule | 21.62 | 13.08 | 29 | 21786 | 22965 | 79699608 |
Breast pain | 21.61 | 13.08 | 18 | 21797 | 8247 | 79714326 |
Hepatocellular injury | 21.41 | 13.08 | 43 | 21772 | 47550 | 79675023 |
FEV1/FVC ratio decreased | 21.36 | 13.08 | 6 | 21809 | 226 | 79722347 |
Hyponatraemic syndrome | 21.21 | 13.08 | 8 | 21807 | 772 | 79721801 |
Obesity | 21.18 | 13.08 | 36 | 21779 | 35089 | 79687484 |
Chronic obstructive pulmonary disease | 20.93 | 13.08 | 61 | 21754 | 85358 | 79637215 |
Dark circles under eyes | 20.87 | 13.08 | 7 | 21808 | 480 | 79722093 |
Procedural haemorrhage | 20.70 | 13.08 | 14 | 21801 | 4692 | 79717881 |
Haemorrhage | 20.37 | 13.08 | 63 | 21752 | 91055 | 79631518 |
Pulmonary embolism | 19.66 | 13.08 | 96 | 21719 | 171558 | 79551015 |
Loss of consciousness | 19.29 | 13.08 | 94 | 21721 | 167849 | 79554724 |
Hand deformity | 18.70 | 13.08 | 3 | 21812 | 103916 | 79618657 |
Arthralgia | 18.50 | 13.08 | 87 | 21728 | 571716 | 79150857 |
Pollakiuria | 18.35 | 13.08 | 35 | 21780 | 37282 | 79685291 |
Rheumatoid arthritis | 18.31 | 13.08 | 18 | 21797 | 208452 | 79514121 |
Headache | 18.05 | 13.08 | 105 | 21710 | 653667 | 79068906 |
Medical device site haemorrhage | 17.96 | 13.08 | 5 | 21810 | 182 | 79722391 |
Wrong strength | 17.91 | 13.08 | 5 | 21810 | 184 | 79722389 |
Asthma-chronic obstructive pulmonary disease overlap syndrome | 17.65 | 13.08 | 11 | 21804 | 3210 | 79719363 |
Penile abscess | 17.46 | 13.08 | 3 | 21812 | 9 | 79722564 |
Breast disorder male | 17.22 | 13.08 | 3 | 21812 | 10 | 79722563 |
Testicular swelling | 17.21 | 13.08 | 8 | 21807 | 1302 | 79721271 |
Epididymitis | 17.05 | 13.08 | 9 | 21806 | 1921 | 79720652 |
Body mass index increased | 17.04 | 13.08 | 9 | 21806 | 1924 | 79720649 |
Inferior vena cava dilatation | 16.90 | 13.08 | 7 | 21808 | 864 | 79721709 |
Thrombosis | 16.85 | 13.08 | 56 | 21759 | 84044 | 79638529 |
Vascular dementia | 16.84 | 13.08 | 7 | 21808 | 872 | 79721701 |
Abnormal sleep-related event | 16.76 | 13.08 | 7 | 21808 | 882 | 79721691 |
Pulmonary interstitial emphysema syndrome | 16.56 | 13.08 | 6 | 21809 | 517 | 79722056 |
Hypoaesthesia | 16.31 | 13.08 | 15 | 21800 | 179337 | 79543236 |
Left ventricular dysfunction | 16.08 | 13.08 | 23 | 21792 | 19338 | 79703235 |
Renal failure | 16.07 | 13.08 | 102 | 21713 | 200866 | 79521707 |
Respiratory symptom | 15.89 | 13.08 | 12 | 21803 | 4779 | 79717794 |
Blood immunoglobulin E increased | 15.77 | 13.08 | 13 | 21802 | 5869 | 79716704 |
Bronchial hyperreactivity | 15.70 | 13.08 | 10 | 21805 | 3030 | 79719543 |
Blood testosterone increased | 15.63 | 13.08 | 7 | 21808 | 1045 | 79721528 |
Facial bones fracture | 15.26 | 13.08 | 12 | 21803 | 5070 | 79717503 |
Urine flow decreased | 15.20 | 13.08 | 7 | 21808 | 1114 | 79721459 |
Cerebral haemorrhage | 14.92 | 13.08 | 42 | 21773 | 57631 | 79664942 |
Brain stem haematoma | 14.90 | 13.08 | 4 | 21811 | 127 | 79722446 |
Clostridium test positive | 14.72 | 13.08 | 13 | 21802 | 6441 | 79716132 |
Violence-related symptom | 14.61 | 13.08 | 6 | 21809 | 725 | 79721848 |
Malaise | 14.60 | 13.08 | 201 | 21614 | 489668 | 79232905 |
Hyperkeratosis | 14.49 | 13.08 | 14 | 21801 | 7776 | 79714797 |
Hypoxia | 14.24 | 13.08 | 61 | 21754 | 103182 | 79619391 |
Product dose omission issue | 14.16 | 13.08 | 29 | 21786 | 247508 | 79475065 |
Sputum increased | 14.08 | 13.08 | 11 | 21804 | 4602 | 79717971 |
Arthropathy | 13.67 | 13.08 | 17 | 21798 | 177094 | 79545479 |
Toxic skin eruption | 13.64 | 13.08 | 23 | 21792 | 22270 | 79700303 |
Tongue oedema | 13.63 | 13.08 | 13 | 21802 | 7104 | 79715469 |
Depression | 13.62 | 13.08 | 24 | 21791 | 216766 | 79505807 |
Bronchiectasis | 13.57 | 13.08 | 23 | 21792 | 22363 | 79700210 |
Vomiting | 13.46 | 13.08 | 117 | 21698 | 665711 | 79056862 |
Peripheral sensorimotor neuropathy | 13.35 | 13.08 | 9 | 21806 | 3001 | 79719572 |
Breast induration | 13.31 | 13.08 | 3 | 21812 | 45 | 79722528 |
None
Source | Code | Description |
---|---|---|
ATC | G04CA52 | GENITO URINARY SYSTEM AND SEX HORMONES UROLOGICALS DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY Alpha-adrenoreceptor antagonists |
ATC | G04CB02 | GENITO URINARY SYSTEM AND SEX HORMONES UROLOGICALS DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY Testosterone-5-alpha reductase inhibitors |
FDA MoA | N0000000126 | 5-alpha Reductase Inhibitors |
MeSH PA | D058891 | 5-alpha Reductase Inhibitors |
MeSH PA | D004791 | Enzyme Inhibitors |
MeSH PA | D006727 | Hormone Antagonists |
MeSH PA | D065088 | Steroid Synthesis Inhibitors |
FDA EPC | N0000175836 | 5-alpha Reductase Inhibitor |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Benign prostatic hyperplasia | indication | 266569009 | |
Priapism | contraindication | 6273006 | DOID:9286 |
Orthostatic hypotension | contraindication | 28651003 | |
Oligozoospermia | contraindication | 88311004 | |
Cataract surgery | contraindication | 110473004 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Syncope | contraindication | 271594007 | |
Pregnancy, function | contraindication | 289908002 | |
Dizziness | contraindication | 404640003 | |
Breastfeeding (mother) | contraindication | 413712001 | |
Intraoperative floppy iris syndrome | contraindication | 418801006 | |
High-Grade Prostate Cancer | contraindication |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 12.41 | acidic |
pKa2 | 13.26 | acidic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
3-oxo-5-alpha-steroid 4-dehydrogenase 2 | Enzyme | INHIBITOR | IC50 | 9.20 | WOMBAT-PK | CHEMBL | |||
3-oxo-5-alpha-steroid 4-dehydrogenase 1 | Enzyme | INHIBITOR | IC50 | 8.49 | WOMBAT-PK | CHEMBL | |||
Glycine receptor subunit alpha-1 | Ion channel | EC50 | 6.48 | CHEMBL |
ID | Source |
---|---|
4021371 | VUID |
N0000148790 | NUI |
D03820 | KEGG_DRUG |
4021371 | VANDF |
C0754659 | UMLSCUI |
CHEMBL1200969 | ChEMBL_ID |
D000068538 | MESH_DESCRIPTOR_UI |
DB01126 | DRUGBANK_ID |
7457 | IUPHAR_LIGAND_ID |
7586 | INN_ID |
O0J6XJN02I | UNII |
6918296 | PUBCHEM_CID |
228790 | RXNORM |
16302 | MMSL |
228246 | MMSL |
42738 | MMSL |
d04788 | MMSL |
009824 | NDDF |
385570006 | SNOMEDCT_US |
385572003 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Dutasteride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-1438 | CAPSULE, LIQUID FILLED | 0.50 mg | ORAL | ANDA | 28 sections |
AVODART | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0173-0712 | CAPSULE, LIQUID FILLED | 0.50 mg | ORAL | NDA | 27 sections |
JALYN | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0173-0809 | CAPSULE | 0.50 mg | ORAL | NDA | 29 sections |
JALYN | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0173-0809 | CAPSULE | 0.50 mg | ORAL | NDA | 29 sections |
Dutasteride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0173-7077 | CAPSULE, LIQUID FILLED | 0.50 mg | ORAL | Export only | 2 sections |
Dutasteride and Tamsulosin Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 2 | 10370-280 | CAPSULE | 0.50 mg | ORAL | ANDA | 28 sections |
Dutasteride and Tamsulosin Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 2 | 10370-280 | CAPSULE | 0.50 mg | ORAL | ANDA | 28 sections |
Dutasteride | Human Prescription Drug Label | 1 | 25000-011 | CAPSULE, LIQUID FILLED | 0.50 mg | ORAL | ANDA | 29 sections |
Dutasteride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 31722-131 | CAPSULE, LIQUID FILLED | 0.50 mg | ORAL | ANDA | 18 sections |
Dutasteride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42806-549 | CAPSULE, LIQUID FILLED | 0.50 mg | ORAL | ANDA | 28 sections |
Dutasteride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-4010 | CAPSULE, LIQUID FILLED | 0.50 mg | ORAL | ANDA | 18 sections |
Dutasteride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51013-190 | CAPSULE, LIQUID FILLED | 0.50 mg | ORAL | ANDA | 28 sections |
Dutasteride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-157 | CAPSULE, LIQUID FILLED | 0.50 mg | ORAL | ANDA | 18 sections |
Dutasteride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-157 | CAPSULE, LIQUID FILLED | 0.50 mg | ORAL | ANDA | 18 sections |
Dutasteride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53345-037 | CAPSULE, LIQUID FILLED | 0.50 mg | ORAL | ANDA | 28 sections |
Avodart | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-5114 | CAPSULE, LIQUID FILLED | 0.50 mg | ORAL | NDA | 27 sections |
JALYN | HUMAN PRESCRIPTION DRUG LABEL | 2 | 54868-6328 | CAPSULE | 0.50 mg | ORAL | NDA | 28 sections |
Dutasteride | Human Prescription Drug Label | 1 | 59651-021 | CAPSULE, LIQUID FILLED | 0.50 mg | ORAL | ANDA | 28 sections |
Dutasteride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62112-8068 | CAPSULE, LIQUID FILLED | 0.50 mg | ORAL | ANDA | 27 sections |
Dutasteride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-1222 | CAPSULE, LIQUID FILLED | 0.50 mg | ORAL | ANDA | 18 sections |
Dutasteride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-1222 | CAPSULE, LIQUID FILLED | 0.50 mg | ORAL | ANDA | 18 sections |
Dutasteride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-1222 | CAPSULE, LIQUID FILLED | 0.50 mg | ORAL | ANDA | 18 sections |
Dutasteride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-1223 | CAPSULE, LIQUID FILLED | 0.50 mg | ORAL | ANDA | 18 sections |
Dutasteride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-1223 | CAPSULE, LIQUID FILLED | 0.50 mg | ORAL | ANDA | 18 sections |
Dutasteride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-1223 | CAPSULE, LIQUID FILLED | 0.50 mg | ORAL | ANDA | 18 sections |
Dutasteride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-8207 | CAPSULE, LIQUID FILLED | 0.50 mg | ORAL | ANDA | 18 sections |
Dutasteride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-8207 | CAPSULE, LIQUID FILLED | 0.50 mg | ORAL | ANDA | 18 sections |
Dutasteride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64380-763 | CAPSULE, LIQUID FILLED | 0.50 mg | ORAL | ANDA | 25 sections |
DUTASTERIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64980-224 | CAPSULE, LIQUID FILLED | 0.50 mg | ORAL | ANDA | 26 sections |
Dutasteride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65162-750 | CAPSULE | 0.50 mg | ORAL | ANDA | 18 sections |